In our case, the patient was a young man who responded well to PAH-targeted drugs, unlike in previous studies, which may be related to pulmonary vascular cell proliferation and microvascular remodeling associated with the EIF2AK4 biallelic dysfunction mutation. This evidence concerns the gene EIF2AK4 and pulmonary arterial hypertension.